This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication

This study has been completed.
TNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti.
TC Erciyes University
Information provided by:
Deva Holding A.S. Identifier:
First received: May 12, 2010
Last updated: August 8, 2011
Last verified: August 2011
Today, although the triple treatment with clarithromycin accepted as the primary treatment for Helicobacter pylori infection eradication is well tolerated, the eradication has been decreased to 65 %. However, the eradication resulting from TRIOL treatment with levofloxacin is expected to be 75 % or higher. If the target results can be reached, it will be concluded that TRIOL treatment with levofloxacin will be an alternative to the triple treatment with clarithromycin as the primary treatment.

Condition Intervention Phase
Helicobacter Pylori Infection Drug: Levofloxacin Drug: Amoxicillin Drug: Lansoprazole Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Monocentric, Open-label, Efficacy and Safety Evaluation Study of the Triple Therapy of 500 mg Levofloxacin, 1000 mg Amoxicillin and 30 mg Lansoprazole on Helicobacter Pylori Eradication in 60 Patients Infected With H. Pylori

Resource links provided by NLM:

Further study details as provided by Deva Holding A.S.:

Primary Outcome Measures:
  • Helicobacter pylori infection eradication [ Time Frame: 6 weeks ]
    After 6 weeks from the end of the TRIOL treatment, demonstrating the ratio of patients who do not develop Helicobacter pylori infection by rapid urease test and Giemsa staining.

Secondary Outcome Measures:
  • Safety [ Time Frame: 6 weeks ]
    During the study all patients will be examined at the determined timepoints in the protocol in regard to any type of clinical adverse event. These examinations involve clinical and laboratory examinations of which the results will be recorded in the final study report and discussed with respect to the current literature.

Estimated Enrollment: 60
Study Start Date: June 2010
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Levofloxacin
    tablet, 500 mg, once a day for ten days
    Other Name: Floxilevo 500 mg Tablet
    Drug: Amoxicillin
    tablet, 1000 mg, once a day for ten days
    Other Name: Dentamax 1 gr Tablet
    Drug: Lansoprazole
    capsule, 30 mg, twice a day for ten days
    Other Name: Degastrol 30 mg Capsule
Detailed Description:
The primary end point in this study is appointed to be "Helicobacter pylori infection eradication with TRIOL treatment" and the secondary end point as "safety". The study involves the investigation of the efficacy and safety of the triple treatment consisting of 500 mg levofloxacin, 1000 mg amoxicillin and 30 mg lansoprazole on Helicobacter pylori eradication in 60 patients with Helicobacter pylori infection.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Consenting to an endoscopy
  • Signing the informed consent form
  • Not receiving Helicobacter pylori eradication treatment before
  • Showing Helicobacter pylori infection by rapid urease test and/or Giemsa staining
  • Being older than 18 years of age

Exclusion Criteria:

  • Being younger than 18 years of age
  • Receiving H. pylori eradication treatment previously
  • Having gastrectomy or vagotomy in medical history
  • Having gastric malignancy, including adenocarcinoma and lymphoma
  • Having other severe malignant disease
  • Previously having allergic reaction to antibiotics (amoxicillin, levofloxacin) and proton pump inhibitors (lansoprazole)
  • Using prompt pump inhibitors (lansoprazole) and antibiotics (amoxicillin, clarithromycin, levofloxacin) in the last 4 weeks
  • Having active upper GI bleeding in the last week
  • Being pregnant or lactating
  • Taking long term high dosages of aspirin, corticosteroid and other NSAIDs in the last 4 weeks
  • Taking any antibiotics or proton pump inhibitors other than the study medication during the study period
  • Taking antacids and/or H2-blockers during the study period
  • Taking bismuth compounds within four weeks prior to and during the study period
  • Having dysphasia or vomiting as major symptoms
  • Having psychiatric, neurological, or behavioral disorders that may interfere with the conduct or interpretation of the study
  • Having severe concomitant disease of the cardiovascular, pulmonic, hepatic, renal, hematological, lymphatic, metabolic, and endocrine system.
  • Having known uncontrolled hypertension
  • Being immunocompromised
  • Showing clinically significant abnormal vital signs
  • Having clinically significant abnormal ECG findings
  • Presenting clinically significant abnormal laboratory data at screening, or any abnormal laboratory value that could interfere with the assessment of safety
  • Being exposed to any investigational drug within 30 days prior to screening
  • Having known hypersensitivity to or contraindication against fluoroquinolones.
  • Having current diagnosis or known history of substance abuse.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01131026

Erciyes University School of Medicine Hospital, Department of Internal Medicine and Gastroenterology
Kayseri, Turkey, 38039
Sponsors and Collaborators
Deva Holding A.S.
TNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti.
TC Erciyes University
Principal Investigator: Mehmet Yucesoy, MD Kayseri, Erciyes University School of Medicine Hospital, Department of Internal Medicine and Gastroenterology
Study Director: Recep S Alpan, MD, PhD, MSc TNC Pharmaceuticals Research, Development and Consultancy Ltd.
  More Information

Responsible Party: Prof. Dr. R. Serdar Alpan, MD, PhD, MSc, TNC İlac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti. Identifier: NCT01131026     History of Changes
Other Study ID Numbers: DV-09-0015
Study First Received: May 12, 2010
Last Updated: August 8, 2011

Keywords provided by Deva Holding A.S.:
Helicobacter pylori
triple therapy

Additional relevant MeSH terms:
Helicobacter Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Infective Agents, Urinary
Renal Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors processed this record on August 18, 2017